Medical expertise firm AngioDynamics, Inc. (NASDAQ: ANGO) Wednesday reported a narrower web loss for the third quarter of 2025. Revenues decreased by 4%.
Web loss, excluding particular gadgets, was $0.08 per share within the February quarter, in comparison with a lack of $0.16 per share within the corresponding interval of 2024. On an unadjusted foundation, web loss narrowed to $4.41 million or $0.11 per share in Q2 from $187.7 million or $4.67 per share within the prior-year quarter.
Revenues, on a reported foundation, decreased 4% year-over-year to $72.0 million within the third quarter. The corporate expects fiscal 2025 gross sales to be within the vary of $285 million to $288 million.
Commenting on the outcomes, AngioDynamics’ CEO Jim Clemmer mentioned, “Based mostly on the standard of efficiency
we now have seen by means of fiscal 2025, we’re rising our fiscal full-year steering for all of our key metrics, together with; whole worldwide income, MedTech income development, gross margin, adjusted EBITDA, and adjusted EPS.”
